The CEO of Compass Pathways said Wednesday that the company, which is preparing to complete the submission of its psychedelic therapy for regulatory review this quarter, will “go slow before we go fast,” warning that negative patient or provider experiences early in the launch could damage the broader sector.
As the psychedelics field races toward its first potential approval by the Food and Drug Administration, the executive, Kabir Nath, underscored that a cautious rollout would be essential. But he also said the mental health field was on the brink of a major change.